Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Preclinical behavioral models for predicting antipsychotic activity.

Castagné V, Moser PC, Porsolt RD.

Adv Pharmacol. 2009;57:381-418. doi: 10.1016/S1054-3589(08)57010-4. Epub 2009 Nov 27. Review.

PMID:
20230767
2.

Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation.

Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, Jang S, Haggarty SJ, Kokel D, Rubin LL, Peterson RT, Schier AF.

Science. 2010 Jan 15;327(5963):348-51. doi: 10.1126/science.1183090.

3.

Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization.

Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, Peachey NS, Nathans J.

Cell. 2009 Oct 16;139(2):285-98. doi: 10.1016/j.cell.2009.07.047. Erratum in: Cell. 2010 Apr 2;141(1):191.

4.

Test-retest reliability of saccadic measures in subjects at risk for Huntington disease.

Blekher T, Weaver MR, Cai X, Hui S, Marshall J, Jackson JG, Wojcieszek J, Yee RD, Foroud TM.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5707-11. doi: 10.1167/iovs.09-3538. Epub 2009 Jun 24.

PMID:
19553607
5.

Distinct roles of transcription factors brn3a and brn3b in controlling the development, morphology, and function of retinal ganglion cells.

Badea TC, Cahill H, Ecker J, Hattar S, Nathans J.

Neuron. 2009 Mar 26;61(6):852-64. doi: 10.1016/j.neuron.2009.01.020.

6.

Pharmacological treatment effects on eye movement control.

Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA.

Brain Cogn. 2008 Dec;68(3):415-35. doi: 10.1016/j.bandc.2008.08.026. Review.

7.

Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.

Wood MD, Wren PB.

Prog Brain Res. 2008;172:213-30. doi: 10.1016/S0079-6123(08)00911-4. Review.

PMID:
18772035
8.

Neuro-ophthalmological signs during rapid intravenous administration of phenytoin.

Hogan RE, Collins SD, Reed RC, Remler BF.

J Clin Neurosci. 1999 Nov;6(6):494-7.

PMID:
18639188
9.

Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios.

McDonald K, Trick L, Boyle J.

Hum Psychopharmacol. 2008 Oct;23(7):555-70. doi: 10.1002/hup.962. Review.

PMID:
18618902
10.
11.

Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs.

Winter MJ, Redfern WS, Hayfield AJ, Owen SF, Valentin JP, Hutchinson TH.

J Pharmacol Toxicol Methods. 2008 May-Jun;57(3):176-87. doi: 10.1016/j.vascn.2008.01.004. Epub 2008 Feb 9.

PMID:
18337127
12.

Saccadic impairments in Huntington's disease.

Peltsch A, Hoffman A, Armstrong I, Pari G, Munoz DP.

Exp Brain Res. 2008 Apr;186(3):457-69. doi: 10.1007/s00221-007-1248-x. Epub 2008 Jan 10.

PMID:
18185924
13.

A novel method for automatic quantification of psychostimulant-evoked route-tracing stereotypy: application to Mus musculus.

Bonasera SJ, Schenk AK, Luxenberg EJ, Tecott LH.

Psychopharmacology (Berl). 2008 Mar;196(4):591-602. Epub 2007 Dec 21.

14.

A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior.

Hall DA, Stanis JJ, Marquez Avila H, Gulley JM.

Psychopharmacology (Berl). 2008 Jan;195(4):469-78. Epub 2007 Sep 17.

15.

Drug development for CNS disorders: strategies for balancing risk and reducing attrition.

Pangalos MN, Schechter LE, Hurko O.

Nat Rev Drug Discov. 2007 Jul;6(7):521-32. Review.

PMID:
17599084
16.

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R.

Hum Mol Genet. 2007 Aug 1;16(15):1845-61. Epub 2007 May 21.

PMID:
17519223
17.

Invertebrate animal models of diseases as screening tools in drug discovery.

Ségalat L.

ACS Chem Biol. 2007 Apr 24;2(4):231-6. Review.

PMID:
17455900
18.
19.

Novel approach to the behavioural characterization of inbred mice: automated home cage observations.

de Visser L, van den Bos R, Kuurman WW, Kas MJ, Spruijt BM.

Genes Brain Behav. 2006 Aug;5(6):458-66.

20.

Saccades in presymptomatic and early stages of Huntington disease.

Blekher T, Johnson SA, Marshall J, White K, Hui S, Weaver M, Gray J, Yee R, Stout JC, Beristain X, Wojcieszek J, Foroud T.

Neurology. 2006 Aug 8;67(3):394-9. Epub 2006 Jul 19.

PMID:
16855205

Supplemental Content

Support Center